SCHEMBL20488181

SCHEMBL20488181

COC(=O)C(=O)CC(=O)c1nc2ccccc2n1C

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 2/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
LMNA P02545 2/20 0.47
RECQL P46063 2/20 0.47
HTT P42858 1/20 0.47
KLK5 Q9Y337 1/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
MAPT P10636 2/20 0.44
TP53 P04637 1/20 0.44
HPGD P15428 1/20 0.44
ALDH1A1 P00352 3/20 0.44
POLB P06746 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 2/20 0.43
HSD17B10 Q99714 1/20 0.43
ALPL P05186 1/20 0.43
ALPG P10696 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32688299 0.80 KDM4E (0.57) SMN1; SMN2LMNARECQLHTTKLK5
SCHEMBL2596342 0.79 SMN1; SMN2 (0.53) HDAC6SMN1; SMN2LMNARECQLHTT
SCHEMBL23617657 0.79 SMN1; SMN2 (0.48) HDAC6SMN1; SMN2LMNARECQLHTT
SCHEMBL2097340 0.78 HDAC6 (0.50) HDAC6SMN1; SMN2LMNARECQLHTT
SCHEMBL15332510 0.75 HDAC6 (0.48) HDAC6SMN1; SMN2LMNARECQLHTT
SCHEMBL6990517 0.75 SMN1; SMN2 (0.55) HDAC6SMN1; SMN2LMNARECQLHTT
SCHEMBL11401031 0.75 KLK5 (0.60) HDAC6SMN1; SMN2LMNARECQLHTT
SCHEMBL760729 0.74 SMN1; SMN2 (0.57) HDAC6SMN1; SMN2LMNARECQLHTT
SCHEMBL2729927 0.74 SMN1; SMN2 (0.61) HDAC6SMN1; SMN2LMNARECQLHTT
SCHEMBL20893365 0.72 RAB9A (0.57) HDAC6SMN1; SMN2LMNARECQLHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230012463-A1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME ASSEMBLY BIOSCIENCES INC (US) 2023-01-12 US disclosed
US-11078170-B2 Cyclic sulfamide compounds and methods of using same ASSEMBLY BIOSCIENCES, INC. (US) 2021-08-03 US disclosed
US-11078170-B2 Cyclic sulfamide compounds and methods of using same ASSEMBLY BIOSCIENCES, INC. (US) 2021-08-03 US disclosed
EP-3589630-B1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME ASSEMBLY BIOSCIENCES INC (US) 2021-07-07 EP disclosed
EP-3589630-B1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME ASSEMBLY BIOSCIENCES INC (US) 2021-07-07 EP disclosed
US-20200157070-A1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME ASSEMBLY BIOSCIENCES INC (US) 2020-05-21 US disclosed
US-20200157070-A1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME ASSEMBLY BIOSCIENCES INC (US) 2020-05-21 US disclosed
CN-110621672-A Cyclic sulfonamide compounds and methods of use thereof 组装生物科学股份有限公司 2019-12-27 CN disclosed
WO-2018160878-A1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME ASSEMBLY BIOSCIENCES, INC. (US) 2018-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230012463-A1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME HCCS, HAVCR2, SLC10A1 HDAC6 1165/4885SMN1; SMN2 4446/4885LMNA 4105/4885
US-11078170-B2 Cyclic sulfamide compounds and methods of using same HCCS, HAVCR2, SLC10A1 HDAC6 1165/4885SMN1; SMN2 4446/4885LMNA 4105/4885
US-20200157070-A1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME HCCS, HAVCR2, SLC10A1 HDAC6 1165/4885SMN1; SMN2 4446/4885LMNA 4105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.